- Home
- ADMA
ADMA
ADMA Biologics Inc
as 05-20-2024 1:33pm EST
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RAMSEY |
| Market Cap: | 2.1B | IPO Year: | N/A |
| Target Price: | $10.50 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.06 - $9.33 | Next Earning Date: | 05-09-2024 |
| Revenue: | $283,176,466 | Revenue Growth: | 55.68% |
| Revenue Growth (this year): | 31.89% | Revenue Growth (next year): | 16.77% |
Share on Social Networks:
Stock Insider Trading Activity of ADMA Biologics Inc (ADMA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ELMS STEVE | ADMA | Director | Mar 18 '24 | Sell | $6.08 | 411,829 | $2,503,920.32 | 2,115,671 | SEC Form 4 |
| ELMS STEVE | ADMA | Director | Mar 18 '24 | Sell | $6.01 | 49,887 | $299,820.87 | 2,527,500 | SEC Form 4 |
| ELMS STEVE | ADMA | Director | Mar 13 '24 | Sell | $6.21 | 407,000 | $2,527,470.00 | 3,208,671 | SEC Form 4 |
| ELMS STEVE | ADMA | Director | Mar 13 '24 | Sell | $6.05 | 448,276 | $2,712,069.80 | 2,760,395 | SEC Form 4 |
| ELMS STEVE | ADMA | Director | Mar 13 '24 | Sell | $6.01 | 183,008 | $1,099,878.08 | 2,577,387 | SEC Form 4 |
Latest ADMA Biologics Inc News
ADMA Breaking Stock News: Dive into ADMA Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Zacks.com featured highlights ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education
Zacks
5 days ago
5 Stocks With Recent Price Strength to Tap May's Rally
Zacks
7 days ago
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Simply Wall St.
9 days ago
ADMA Biologics First Quarter 2024 Earnings: Beats Expectations
Insider Monkey
10 days ago
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Call Transcript
GuruFocus.com
10 days ago
ADMA Biologics Inc (ADMA) Surpasses Analyst Revenue and Earnings Forecasts in Q1 2024
MT Newswires
10 days ago
Update: ADMA Biologics Shares Rise After Company Swings to Q1 Earnings, Lifts 2024 Guidance
MT Newswires
10 days ago